Kyntra Bio, Inc.

Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs. Its pipeline includes FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, and Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity. Roxadustat has completed Phase III development for anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, and is in Phase III development for anemia related to myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. It was formerly known as FibroGen, Inc. and changed its name to Kyntra Bio, Inc. in January 2026. Incorporated in 1993, it is headquartered in San Francisco, California.